Get the latest market trends in your inbox

Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa-St. Petersburg news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Demonstrators in New York City seeking to end racial bias in marijuana arrests. Photo: Erik McGregor/Pacific Press/LightRocket via Getty Images

With states rapidly legalizing marijuana, concerns are growing among social justice advocates that people of color — who have been disproportionately harmed by the war on drugs — do not have equitable access to the burgeoning cannabis industry.

The big picture: Less than a fifth of marijuana business owners identify as racial minorities, and only 4.3% are African American, according to a survey by Marijuana Business Daily.

”Axios on HBO" spoke to Kika Keith, a community organizer and applicant to L.A.’s social equity program, who has been paying rent on an empty storefront for almost a year — but is still waiting for a license to open her business.

  • “Don't give us any handouts, but give us that opportunity to compete,” she says.

Pot means a potential windfall, at least for the few: 

  • When former politician John Boehner joined the board of U.S. marijuana company Acreage Holdings, he was granted shares currently worth about $12 million. If the company gets sold as anticipated, Boehner's stake will be closer to $20 million. 
  • Boehner was "unalterably opposed" to legalization when he was a politician, a stance that had significant criminal-justice consequences.
  • He told "Axios on HBO": "I don't know that there's any harm that's been done" by any delay in legalizing marijuana.
  • The main obstacle facing people of color interested in breaking into the legal marijuana business, said Boehner, is access to capital.

The bottom line: L.A. has yet to issue a single license to a social-equity applicant who wants to open a retail dispensary. Meanwhile, the overwhelmingly white executives and venture capitalists behind North America's largest marijuana companies are already sitting on billions of dollars in stock.

Go deeper:

Go deeper

6 hours ago - Health

Food banks feel the strain without holiday volunteers

People wait in line at Food Bank Community Kitchen on Nov. 25 in New York City. Photo: Michael Loccisano/Getty Images for Food Bank For New York City

America's food banks are sounding the alarm during this unprecedented holiday season.

The big picture: Soup kitchens and charities, usually brimming with holiday volunteers, are getting far less help.

8 hours ago - Health

AstraZeneca CEO: "We need to do an additional study" on COVID vaccine

Photo: Pavlo Gonchar/SOPA Images/LightRocket via Getty Images

AstraZeneca CEO Pascal Soriot said on Thursday the company is likely to start a new global trial to measure how effective its coronavirus vaccine is, Bloomberg reports.

Why it matters: Following Phase 3 trials, Oxford and AstraZeneca said their vaccine was 90% effective in people who got a half dose followed by a full dose, and 62% effective in people who got two full doses.

Updated 11 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Health: Coronavirus cases rose 10% in the week before Thanksgiving.
  2. Politics: Supreme Court backs religious groups on New York coronavirus restrictions.
  3. World: Expert says COVID vaccine likely won't be available in Africa until Q2 of 2021 — Europeans extend lockdowns.
  4. Economy: The winners and losers of the COVID holiday season.
  5. Education: National standardized tests delayed until 2022.